思瑞浦(688536.SH):目前在美國、韓國、新加坡等地區已建立或正在籌備佈局相關銷售中心
格隆匯9月4日丨思瑞浦(688536.SH)在接受調研時表示,2023年,公司加快推進海外銷售佈局步伐,目前在美國、歐洲、日本、韓國、新加坡等地區已建立或正在籌備佈局相關銷售中心,團隊成員也將陸續到位。
海外龍頭客户基於供應連續性及商業方面的考量,往往有較大動力引入具有競爭力的新增供應商。長期維度上看,公司對於未來海外業務的發展抱有信心,也會努力做好全球化人才團隊建設及業務佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.